A new class of drugs targeting the brain's orexin system is generating excitement in neuroscience and psychiatry, with comparisons to how GLP-1 receptor agonists like Ozempic and Wegovy revolutionized the treatment of obesity and diabetes.
Orexins are neuropeptides that regulate wakefulness, appetite, and stress. Orexin receptor agonists — drugs that activate these receptors — are showing remarkable results in clinical trials for narcolepsy, a condition caused by loss of orexin-producing neurons. But their potential extends far beyond sleep disorders.
Early-stage trials suggest orexin agonists could help treat ADHD, depression, anxiety, and other neurological conditions. The drugs appear to restore the brain's natural ability to maintain alertness and emotional regulation, rather than simply masking symptoms.
"The brain may be about to have its Ozempic moment," The Economist reported this month, drawing parallels between the two drug classes. Both work by targeting a specific biological pathway that was poorly understood until recently, and both have shown unexpected benefits across multiple conditions.
The comparison is significant because GLP-1 drugs have become a $50 billion annual market. If orexin agonists deliver on even a fraction of their potential, they could create a similarly transformative market for neurology and psychiatry.
Phase III trials for the leading orexin agonist in narcolepsy are expected to report results later this year. The narcolepsy results will be closely watched not just by sleep specialists, but by psychiatrists and neurologists who see the drugs' potential for broader applications.
